Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer.
Saved in:
| Title: | Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer. |
|---|---|
| Authors: | Otsuka K; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Isobe J; Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan., Asai Y; Department of Systems Bioinformatics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.; AI Systems Medicine Research and Training Center, Graduate School of Medicine, Yamaguchi University and Yamaguchi University Hospital, Yamaguchi, Japan., Nakano T; Department of Systems Bioinformatics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan., Hattori K; Research Center for Drug Discovery and Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.; Division of Biochemistry, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan., Ariyoshi T; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Yamashita T; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Motegi K; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Saito A; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Kohmoto M; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Hosonuma M; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Kuramasu A; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Baba Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Murayama M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.; Department of Otorhinolaryngology-Head and Neck Surgery, Showa University School of Medicine, Tokyo, Japan., Narikawa Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.; Department of Otorhinolaryngology-Head and Neck Surgery, Showa University School of Medicine, Tokyo, Japan., Toyoda H; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.; Department of Orthopedic Surgery, School of Medicine, Showa University, Tokyo, Japan., Funayama E; Division of Pharmacology, Department of Pharmacology, School of Pharmacy, Showa University, Tokyo, Japan., Tajima K; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Gastroenterological Surgery, Tokai University School of Medicine, Tokyo, Japan., Shida M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Hirasawa Y; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tsurui T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Ariizumi H; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Ishiguro T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Suzuki R; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Ohkuma R; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Kubota Y; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Sambe T; Division of Clinical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan., Tsuji M; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Wada S; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Kiuchi Y; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Kobayashi S; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Horiike A; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Goto S; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Murakami M; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Kim YG; Research Center for Drug Discovery and Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan., Tsunoda T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Yoshimura K; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan. kyoshim1@med.showa-u.ac.jp.; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan. kyoshim1@med.showa-u.ac.jp.; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan. kyoshim1@med.showa-u.ac.jp.; Pharmacological Research Center, Showa University, Tokyo, Japan. kyoshim1@med.showa-u.ac.jp. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Jan 27; Vol. 73 (2), pp. 23. Date of Electronic Publication: 2024 Jan 27. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0851 |
|---|---|
| DOI: | 10.1007/s00262-023-03608-y |
